HCPCS Service Codes - Medical care

HCPCS Codes for Medical care

• G9802

  Patients who use hospice services any time during the measurement period

• G9803

  Patient prescribed at least a 135 day treatment within the 180-day measurement interval with beta-blockers post-discharge for ami

• G9804

  Patient was not prescribed at least a 135 day treatment within the 180-day measurement interval with beta-blockers post-discharge for ami

• G9805

  Patients who use hospice services any time during the measurement period

• G9806

  Patients who received cervical cytology or an hpv test

• G9807

  Patients who did not receive cervical cytology or an hpv test

• G9808

  Any patients who had no asthma controller medications dispensed during the measurement year

• G9809

  Patients who use hospice services any time during the measurement period

• G9810

  Patient achieved a pdc of at least 75% for their asthma controller medication

• G9811

  Patient did not achieve a pdc of at least 75% for their asthma controller medication

• G9812

  Patient died including all deaths occurring during the hospitalization in which the operation was performed, even if after 30 days, and those deaths occurring after discharge from the hospital, but within 30 days of the procedure

• G9813

  Patient did not die within 30 days of the procedure or during the index hospitalization

• G9814

  Death occurring during the index acute care hospitalization

• G9815

  Death did not occur during the index acute care hospitalization

• G9816

  Death occurring after discharge from the hospital but within 30 days post procedure

• G9817

  Death did not occur after discharge from the hospital within 30 days post procedure

• G9818

  Documentation of sexual activity

• G9819

  Patients who use hospice services any time during the measurement period

• G9820

  Documentation of a chlamydia screening test with proper follow-up

• G9821

  No documentation of a chlamydia screening test with proper follow-up

• G9822

  Patients who had an endometrial ablation procedure during the 12 months prior to the index date (exclusive of the index date)

• G9823

  Endometrial sampling or hysteroscopy with biopsy and results documented during the 12 months prior to the index date (exclusive of the index date) of the endometrial ablation

• G9824

  Endometrial sampling or hysteroscopy with biopsy and results not documented during the 12 months prior to the index date (exclusive of the index date) of the endometrial ablation

• G9825

  Her-2/neu negative or undocumented/unknown

• G9826

  Patient transferred to practice after initiation of chemotherapy

• G9827

  Her2-targeted therapies not administered during the initial course of treatment

• G9828

  Her2-targeted therapies administered during the initial course of treatment

• G9829

  Breast adjuvant chemotherapy administered

• G9830

  Her-2/neu positive

• G9831

  Ajcc stage at breast cancer diagnosis = ii or iii

• G9832

  Ajcc stage at breast cancer diagnosis = i (ia or ib) and t-stage at breast cancer diagnosis = t1c

• G9833

  Patient transfer to practice after initiation of chemotherapy

• G9834

  Patient has metastatic disease at diagnosis

• G9835

  Trastuzumab administered within 12 months of diagnosis

• G9836

  Reason for not administering trastuzumab documented (e.g. patient declined, patient died, patient transferred, contraindication or other clinical exclusion, neoadjuvant chemotherapy or radiation not complete)

• G9837

  Trastuzumab not administered within 12 months of diagnosis

• G9838

  Patient has metastatic disease at diagnosis

• G9839

  Anti-egfr monoclonal antibody therapy

• G9840

  Ras (kras and nras) gene mutation testing performed before initiation of anti-egfr moab

• G9841

  Ras (kras and nras) gene mutation testing not performed before initiation of anti-egfr moab

• G9842

  Patient has metastatic disease at diagnosis

• G9843

  Ras (kras or nras) gene mutation

• G9844

  Patient did not receive anti-egfr monoclonal antibody therapy

• G9845

  Patient received anti-egfr monoclonal antibody therapy

• G9846

  Patients who died from cancer

• G9847

  Patient received systemic cancer-directed therapy in the last 14 days of life

• G9848

  Patient did not receive systemic cancer-directed therapy in the last 14 days of life

• G9849

  Patients who died from cancer

• G9850

  Patient had more than one emergency department visit in the last 30 days of life

• G9851

  Patient had one or less emergency department visits in the last 30 days of life